OncoMatch/Clinical Trials/NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Is NCT07286149 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for lung neoplasm malignant.
Treatment: MK-1084 · Patritumab deruxtecan · Sacituzumab tirumotecan · Cetuximab · Rescue Medications — Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Prior therapy
Must have received: anti-PD-1 therapy
disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy
Must have received: anti-PD-L1 therapy
disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy
Must have received: platinum-based chemotherapy
disease progression after receiving 1-2 prior lines of ... platinum-based chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clermont Oncology Center ( Site 0041) · Clermont, Florida
- University of Illinois Hospital & Health Sciences System ( Site 0044) · Chicago, Illinois
- Providence Portland Medical Center ( Site 0043) · Portland, Oregon
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059) · Portland, Oregon
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07286149 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anti-PD-1 therapy and anti-PD-L1 therapy.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages